Silverarc Capital Management
Latest statistics and disclosures from Silverarc Capital Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are ASND, CELC, COGT, URGN, IMNM, and represent 25.74% of Silverarc Capital Management's stock portfolio.
- Added to shares of these 10 stocks: ASND (+$55M), ELVN (+$25M), SGMT (+$23M), Ark Etf Tr (+$21M), ORKA (+$19M), DFTX (+$19M), CELC (+$15M), ALXO (+$12M), MANE (+$12M), Avalyn Pharma (+$11M).
- Started 26 new stock positions in CNTB, Kymera Therapeutics, SLDB, Research Alliance Corp Iii, ALXO, WGS, Absci Corporation, SGMT, ELVN, ACRS.
- Reduced shares in these 10 stocks: , Kalvista Pharmaceuticals (-$58M), NUVL (-$36M), Ascendis Pharma A S (-$29M), DNTH (-$26M), GLUE (-$22M), Centessa Pharmaceuticals (-$19M), ALKS (-$18M), ABVX (-$18M), KOD (-$17M).
- Sold out of its positions in AARD, ANNX, Ascendis Pharma A S, Celcuity, CLDX, Centessa Pharmaceuticals, CGON, CMPX, Compass Therapeutics, CYTK.
- Silverarc Capital Management was a net seller of stock by $-147M.
- Silverarc Capital Management has $962M in assets under management (AUM), dropping by -1.80%.
- Central Index Key (CIK): 0001816307
Tip: Access up to 7 years of quarterly data
Positions held by Silverarc Capital Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Silverarc Capital Management
Silverarc Capital Management holds 73 positions in its portfolio as reported in the June 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Ascendis Pharma A/s Ord Shs (ASND) | 5.7 | $55M | NEW | 206k | 266.72 |
|
| Celcuity (CELC) | 5.4 | $52M | +39% | 501k | 104.62 |
|
| Cogent Biosciences (COGT) | 5.2 | $50M | -2% | 1.3M | 38.70 |
|
| Urogen Pharma (URGN) | 5.0 | $48M | -13% | 1.3M | 36.80 |
|
| Immunome (IMNM) | 4.4 | $43M | +9% | 2.0M | 21.19 |
|
| Dianthus Therapeutics (DNTH) | 4.0 | $38M | -40% | 390k | 97.48 |
|
| Rhythm Pharmaceuticals (RYTM) | 3.6 | $35M | 312k | 111.03 |
|
|
| Oruka Therapeutics (ORKA) | 3.5 | $34M | +133% | 353k | 95.17 |
|
| Monte Rosa Therapeutics (GLUE) | 2.8 | $27M | -44% | 1.1M | 24.20 |
|
| Syndax Pharmaceuticals (SNDX) | 2.8 | $27M | +36% | 1.2M | 21.86 |
|
| Enliven Therapeutics (ELVN) | 2.6 | $25M | NEW | 489k | 50.75 |
|
| Immunovant (IMVT) | 2.5 | $24M | +49% | 619k | 38.53 |
|
| Erasca (ERAS) | 2.4 | $23M | -31% | 1.3M | 18.32 |
|
| Sagimet Biosciences Com Ser A (SGMT) | 2.4 | $23M | NEW | 2.9M | 7.73 |
|
| Abivax Sa Sponsored Ads (ABVX) | 2.3 | $23M | -43% | 170k | 133.26 |
|
| Praxis Precision Medicines I Com New (PRAX) | 2.3 | $22M | -8% | 66k | 334.79 |
|
| Kodiak Sciences (KOD) | 2.2 | $21M | -44% | 546k | 38.96 |
|
| Ark Etf Tr Put Put Option | 2.2 | $21M | NEW | 500k | 42.06 |
|
| Definium Therapeutics Com Shs (DFTX) | 2.0 | $19M | NEW | 400k | 47.04 |
|
| Veracyte (VCYT) | 1.9 | $19M | +76% | 318k | 58.73 |
|
| Syndax Pharmaceuticals Call Call Option | 1.6 | $15M | +116% | 694k | 21.86 |
|
| Guardant Health (GH) | 1.6 | $15M | 100k | 150.03 |
|
|
| C4 Therapeutics Com Stk (CCCC) | 1.5 | $14M | +58% | 3.0M | 4.67 |
|
| Zenas Biopharma (ZBIO) | 1.3 | $13M | -55% | 510k | 25.38 |
|
| Trevi Therapeutics (TRVI) | 1.3 | $13M | +32% | 678k | 18.65 |
|
| Helix Acquisition Corp Iii Usd Cl A Ord Shs (HLXC) | 1.3 | $13M | -2% | 1.2M | 10.64 |
|
| Alx Oncology Hldgs (ALXO) | 1.2 | $12M | NEW | 5.7M | 2.07 |
|
| Veradermics Common Stock (MANE) | 1.2 | $12M | NEW | 95k | 122.94 |
|
| Xenon Pharmaceuticals (XENE) | 1.2 | $11M | -5% | 187k | 60.36 |
|
| Avalyn Pharmaceuticals Com Shs | 1.1 | $11M | NEW | 331k | 32.92 |
|
| Biogen Idec (BIIB) | 1.1 | $10M | -5% | 48k | 216.06 |
|
| Aclaris Therapeutics (ACRS) | 1.1 | $10M | NEW | 1.9M | 5.29 |
|
| Cerus Corporation (CERS) | 1.1 | $10M | +9% | 3.5M | 2.92 |
|
| Avalo Therapeutics Com New (AVTX) | 1.0 | $9.2M | NEW | 500k | 18.48 |
|
| Benitec Biopharma Com New (BNTC) | 0.9 | $9.1M | -5% | 680k | 13.38 |
|
| Vaxcyte (PCVX) | 0.9 | $8.4M | 145k | 58.13 |
|
|
| Genedx Holdings Corp Com Cl A (WGS) | 0.9 | $8.4M | NEW | 122k | 68.65 |
|
| Savara (SVRA) | 0.9 | $8.3M | -5% | 1.4M | 6.16 |
|
| Ovid Therapeutics (OVID) | 0.9 | $8.3M | +210% | 3.1M | 2.69 |
|
| Oric Pharmaceuticals (ORIC) | 0.8 | $8.0M | -32% | 739k | 10.83 |
|
| Oric Pharmaceuticals Call Call Option | 0.8 | $7.4M | NEW | 683k | 10.83 |
|
| Monte Rosa Therapeutics Call Call Option | 0.8 | $7.3M | NEW | 300k | 24.20 |
|
| Compass Pathways Sponsored Ads (CMPS) | 0.7 | $7.1M | +67% | 503k | 14.15 |
|
| Compugen Ord (CGEN) | 0.7 | $6.8M | -3% | 3.2M | 2.14 |
|
| Solid Biosciences Com New (SLDB) | 0.7 | $6.7M | NEW | 669k | 9.99 |
|
| Abivax Sa Call Call Option | 0.7 | $6.7M | NEW | 50k | 133.26 |
|
| Ibio Com New (IBIO) | 0.6 | $6.2M | +1457% | 3.5M | 1.75 |
|
| Disc Medicine (IRON) | 0.6 | $6.1M | -57% | 83k | 73.14 |
|
| Alkermes SHS (ALKS) | 0.6 | $5.9M | -75% | 114k | 52.40 |
|
| Spyre Therapeutics Com New (SYRE) | 0.6 | $5.3M | -67% | 60k | 88.78 |
|
| Artiva Biotherapeutics (ARTV) | 0.5 | $5.1M | NEW | 525k | 9.70 |
|
| Contineum Therapeutics Cl A (CTNM) | 0.5 | $4.9M | 296k | 16.39 |
|
|
| Uniqure Nv SHS (QURE) | 0.5 | $4.8M | NEW | 105k | 46.06 |
|
| Research Alliance Corp Iii Ord Shs Cl A | 0.4 | $3.9M | NEW | 360k | 10.70 |
|
| Abeona Therapeutics Com New (ABEO) | 0.4 | $3.8M | -5% | 610k | 6.18 |
|
| Insmed Com Par $.01 (INSM) | 0.4 | $3.7M | -3% | 34k | 106.62 |
|
| Karyopharm Therapeutics Com New (KPTI) | 0.3 | $2.9M | NEW | 298k | 9.77 |
|
| Kymera Therapeutics Put Put Option | 0.3 | $2.9M | NEW | 25k | 114.67 |
|
| Camp4 Therapeutics Corp (CAMP) | 0.3 | $2.9M | 654k | 4.37 |
|
|
| Elutia Cl A Com (ELUT) | 0.2 | $2.1M | -12% | 2.2M | 0.98 |
|
| Revolution Medicines (RVMD) | 0.2 | $1.9M | NEW | 10k | 187.28 |
|
| Sionna Therapeutics (SION) | 0.2 | $1.9M | +7% | 43k | 43.99 |
|
| Absci Corporation Put Put Option | 0.2 | $1.8M | NEW | 158k | 11.59 |
|
| Tela Bio (TELA) | 0.2 | $1.6M | -5% | 2.1M | 0.75 |
|
| Achieve Life Sciences (ACHV) | 0.2 | $1.5M | NEW | 227k | 6.53 |
|
| Fulcrum Therapeutics Call Call Option | 0.1 | $1.4M | 392k | 3.66 |
|
|
| Fractyl Health (GUTS) | 0.1 | $1.3M | -3% | 1.6M | 0.79 |
|
| Connect Biopharma Hldgs SHS (CNTB) | 0.1 | $1.3M | NEW | 545k | 2.38 |
|
| Crescent Biopharma (CBIO) | 0.1 | $1.1M | -54% | 59k | 18.00 |
|
| Cellectar Biosciences Com New (CLRB) | 0.1 | $894k | NEW | 322k | 2.78 |
|
| Foghorn Therapeutics (FHTX) | 0.0 | $224k | NEW | 46k | 4.88 |
|
| Adagio Med Hldgs (ADGM) | 0.0 | $146k | -10% | 224k | 0.65 |
|
| Rocket Pharmaceuticals *w Exp 09/02/202 (RCKTW) | 0.0 | $356.415200 | 105k | 0.00 |
|
Past Filings by Silverarc Capital Management
SEC 13F filings are viewable for Silverarc Capital Management going back to 2020
- Silverarc Capital Management 2026 Q2 filed Aug. 13, 2026
- Silverarc Capital Management 2026 Q1 filed May 14, 2026
- Silverarc Capital Management 2025 Q4 filed Feb. 12, 2026
- Silverarc Capital Management 2025 Q3 filed Nov. 12, 2025
- Silverarc Capital Management 2025 Q2 filed Aug. 14, 2025
- Silverarc Capital Management 2025 Q1 filed May 14, 2025
- Silverarc Capital Management 2024 Q4 filed Feb. 14, 2025
- Silverarc Capital Management 2024 Q3 filed Nov. 14, 2024
- Silverarc Capital Management 2024 Q2 filed Aug. 14, 2024
- Silverarc Capital Management 2024 Q1 filed May 15, 2024
- Silverarc Capital Management 2023 Q4 filed Feb. 14, 2024
- Silverarc Capital Management 2023 Q3 filed Nov. 13, 2023
- Silverarc Capital Management 2023 Q2 filed Aug. 14, 2023
- Silverarc Capital Management 2023 Q1 filed May 15, 2023
- Silverarc Capital Management 2022 Q4 filed Feb. 14, 2023
- Silverarc Capital Management 2022 Q3 filed Oct. 28, 2022